Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Dec 11;91(24):e2222-e2232.
doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16.

Lasmiditan Is an Effective Acute Treatment for Migraine: A Phase 3 Randomized Study

Collaborators, Affiliations
Free PMC article
Clinical Trial

Lasmiditan Is an Effective Acute Treatment for Migraine: A Phase 3 Randomized Study

Bernice Kuca et al. Neurology. .
Free PMC article


Objective: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine.

Methods: Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS).

Results: Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0-3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6-3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3-2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3-2.2, p< 0.001) were free of their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity.

Conclusions: Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors.

Clinicaltrialsgov identifier: NCT02439320.

Classification of evidence: This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.


Figure 1
Figure 1. Study flow (first dose)
ITT = intent-to-treat; L100 = lasmiditan 100 mg; L200 = lasmiditan 200 mg; mITT = modified intent-to-treat. aPatients who were randomized but then deemed ineligible at the telephone confirmation (after completion of all screening evaluations).
Figure 2
Figure 2. Headache pain free, MBS free, and headache relief after the first dose
aDefined as a reduction in (A) headache severity from mild (1), moderate (2), or severe (3) at baseline to none (0). bDefined as (B) the absence of the associated symptom of migraine that was identified before dose as the most bothersome symptom (MBS) (nausea, phonophobia, or photophobia). cDefined as (C) a reduction in headache severity from moderate (2) or severe (3) at baseline to mild (1) or none (0) or a reduction in headache severity from mild (1) at baseline to none (0). *p< 0.05, **p< 0.01, ***p ≤ 0.001 vs placebo. ITT = intent-to-treat; mITT = modified intent-to-treat.

Similar articles

See all similar articles

Cited by 27 articles

See all "Cited by" articles


    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–1259. - PMC - PubMed
    1. Cameron C, Shannon K, Hsieh S, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 2015;55:221–235. - PubMed
    1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368:259–268. - PubMed
    1. Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49–56. - PubMed
    1. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990;600:587–598. - PubMed

Publication types

Associated data